A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)

2상 완료 NCT05258071

요약

This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.

Change in Falls Frequency as Assessed With Fall Diary From Baseline Period (4 Weeks Prior to Randomization) to the End of Treatment.

Baseline to end of full dose treatment (up to Day 84). · % of baseline fall rate

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

• Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given P — Merck Sharp & Dohme LLC
• Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers — Rutgers, The State University of New Jersey
• Evaluation of Advanced Imaging and Visualization for Clinical Deep Brain Stimulation — Duke University
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemot — Merck Sharp & Dohme LLC
• A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advan — Merck Sharp & Dohme LLC
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With E — Hoffmann-La Roche

전체 임상